Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeMARKET REPORTSEpidemiology Forecast Multiple System Atrophy to 2030

Epidemiology Forecast Multiple System Atrophy to 2030

February 12, 2021

Epidemiology Forecast Multiple System Atrophy report delivers an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Multiple System Atrophy (MSA) Disease Understanding

Multiple System Atrophy (MSA), formerly known as Shy-Drager Syndrome, is a rare, degenerative neurological disorder affecting the body’s involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The term multiple system atrophy was first introduced in the medical literature in 1969.

It encompasses three presentations of a single disease formerly thought to be separate disorders, specifically Shy-Drager syndrome (which emphasized autonomic dysfunction), striatonigral degeneration (which emphasized parkinsonian symptoms), and sporadic olivopontocerebellar atrophy (which emphasized cerebellar symptoms).

MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). A patient diagnosed with MSA-P may over time appear to have MSA-C and vice versa, so these categorizations are not always set in stone.

Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA scenario of MSA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Scope of the Report

  • The report covers the descriptive overview of MSA, explaining its signs and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of MSA.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA.

Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of MSA?
  • What is the historical MSA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of MSA at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MSA?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of MSA during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the 7MM MSA epidemiology forecast.
  • The MSA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The MSA epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

For more information about this report visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy